Oral antisense platform · Thailand · USA · Canada
Written in the language of your own DNA.
immugence designs oral antisense candidates — short strands that bind a single messenger-RNA sequence, a lock cut for one key. Built from DNA information, not chemicals. A three-country operation and research across Thailand, the United States and Canada, through immugence and Immunitor.
Peer-reviewed papers
PubMed indexed
Patents granted
US + worldwide IP
US FDA orphan designations
1 granted · 1 submitted
Same team, one lineage
continuous since 2000
Regulatory recognition
Two U.S. FDA orphan-drug designations.
The platform's lineage has earned what almost no first-time company holds: formal recognition from the United States Food & Drug Administration's Office of Orphan Products Development — one granted, one filed.
Hepatocellular carcinoma
V5 · Hepcortespenlisimut-L — liver cancer
FDA Office of Orphan Products Development
Tuberculosis, incl. MDR-TB
V7 · Mycobacterium vaccae — drug-resistant TB
Designation requested · under review
The science
Antisense, explained without the mystique.
The idea is old and well-understood; the hard part is making it work by mouth. Here is exactly what an immugence candidate does — and what it deliberately does not.
One sequence, one target
Each candidate is designed to complement a single messenger-RNA. Like a key cut for one lock, it binds where it should and nowhere else.
RNA-level, not gene editing
Antisense silences a signal by binding mRNA. It does not cut, rewrite, or insert anything into your genome — the DNA is left untouched.
Oral, no viral vector
Carried by a magnesium-chloride matrix and taken by mouth. No injection, no AAV, no lipid nanoparticle to clear.
Why magnesium changes the game
Antisense works. The hard part is delivering it by mouth.
Antisense is proven science — several injectable antisense drugs are already FDA-approved. The genuinely hard problem is making it stable and absorbable as an oral pill. Our answer is a magnesium-chloride matrix (MgCl₂·6H₂O) — a carrier the body already knows.
enzymes use Mg²⁺ as a cofactor
magnesium is not foreign to the body
viral vectors · liposomes · nanoparticles
no immunogenic or toxic carrier
acts at the mRNA level, never the genome
silences a signal, does not edit genes
Head to head
Mg-ASO vs. the industry-standard delivery systems
The properties of each carrier are widely published. This is the design rationale behind our platform.
Why magnesium
A carrier the body does not treat as an enemy.
The magnesium chloride hexahydrate matrix (MgCl₂·6H₂O) makes an antisense strand stable enough to survive the stomach and be absorbed — with no lipids, PEG, or viral capsid. Magnesium is an ion the body already uses in more than 300 enzymes, giving it a safety profile fundamentally different from synthetic carriers.
- Taken by mouth — no injection
- No anti-PEG IgM as seen with LNPs
- No genome-integration risk as with AAV
- Simple, scalable manufacturing
Proprietary platform invented by
Pharm. Vichai Jirathitikal
Why it is gentle
Built from DNA information.
Nothing the body treats as foreign.
An antisense oligonucleotide is a short, designed strand of nucleic acid — the same alphabet your cells already read. It carries information, not a foreign chemical payload. That is the basis of its gentleness, and it is the most honest thing we can tell you about safety.
What it is
A strand of genetic information
a coded message that silences one signal — designed to match a single target, taken by mouth
What it is not
- Synthetic chemicals
- Foreign proteins
- Peptides
- Live cells
- Hormones
The hard questions
“Too good to be true.”
We hear it often — so let's talk.
Skepticism is the correct response to extraordinary claims. We'd rather you bring it than walk away. Here are the four objections we hear most, answered plainly.
Antisense itself is established science — several injectable antisense drugs are already approved by major regulators. The genuinely hard problem we work on is making the chemistry stable and absorbable by mouth. We don't ask you to take that on faith: the mechanism is in the textbooks, and our specific results are in 29 peer-reviewed papers you can read.
Judge the work, not the postcode. Our research is published in international, peer-reviewed journals; our advisors hold positions at institutions such as Mahidol and a Finland Distinguished Professorship; and our laboratory and facility are registered with the Thai FDA. Credibility here is built from verifiable records, listed with their sources.
Because we are early, and we publish before we promote. immugence candidates are investigational and in research and development — we are deliberately not running consumer hype. What exists today is preclinical evidence, granted patents, and FDA orphan-drug designations in progress, each documented on its own page.
No single pill does. immugence is a platform, not a miracle product: each indication is a separate candidate with its own target, its own data, and its own honest stage of development. We make no cure claims, and nothing on this site is a registered treatment.
The receipts
A 25-year published record — the science the platform is built on.
Our founding team's oral-immunotherapy work — through Immunitor, the same corporate family — is indexed, peer-reviewed, and patented. The Mg-ASO antisense platform extends it. Every item below links to its primary source.
Open-label Phase II of oral Hepcortespenlisimut-L in 75 advanced liver-cancer patients
Phase III oral immunotherapy in tuberculosis: 68% clearance vs 23.1% placebo (152 patients)
Randomized Phase IIb in TB: 78.3% sputum conversion vs 0% placebo (p = 0.009)
Orphan-drug designation — Hepcortespenlisimut-L for hepatocellular carcinoma
Viral vaccine composition, process and methods of use — the foundation IP
Oral composition and methods for immunotherapy — metal-bound antisense delivery
In development
Twenty oral candidates. One Mg-ASO platform.
Each candidate adapts the same magnesium-stabilized antisense chemistry to a different target sequence. Stages are shown honestly — most are early; the leading programs draw on the team's published clinical evidence.
For hospitals, clinics & wellness centers
We are a platform — not a competitor.
immugence is a technology and solution provider. We don't open clinics to compete with you; we hand you the science so you become the Center of Excellence. Partners bring our antisense platform into their institution and lead in the area they choose to own.
License the platform
Technology transfer of our antisense chemistry, oral-delivery matrix, and design know-how — under a clear partnership agreement.
Build your Center of Excellence
Stand up a co-branded program in the therapeutic area you choose. Your institution leads; we provide the science underneath it.
You lead, we support
Training, supply, and scientific support from immugence. You own the patient relationship, the brand, and the clinical leadership.
Bangkok · operating nowThe first Center of Excellence
We built the first one ourselves — so you don't have to start from zero.
IMMUNIC is our own antisense clinical-research and demonstration center in Bangkok. It is the reference implementation of the model we hand to partners: proof that the platform runs in the real world, and the template your institution replicates. It is a research setting, not a retail clinic — and it is exactly what your Center of Excellence can look like.
Therapeutic areas open to partners
Candidates available to license
The people accountable
Names, degrees, and track records — on the record.
An unknown company earns trust through the people behind it. Every credential here is verifiable; we'd rather you check than assume.
Vichai Jirathitikal
Pharm. · Co-Founder & CTO
Inventor of the magnesium-stabilized oral antisense platform; principal inventor across the patent portfolio.
immugence · IMMUNIC, Bangkok
Patchalit Klinhorm
Co-Founder & CEO
Brings the platform to market and leads the Centers of Excellence program.
Founder, ECG Venture Capital
Holland Cheng
PhD · Scientific Advisor
Structural biology, cryo-EM and vaccine design; bridges to global academia.
Finland Distinguished Prof. · UC Davis · Karolinska
Pisut Pongchaikul
MD, PhD · Advisor
Medical microbiology, bioinformatics and pathogen genomics.
Asst. Prof., Mahidol University
Jonathan P. Wong
PhD · Advisor
Antisense delivery and antiviral defense; three decades at DRDC Canada.
Director, Dove Pharmaceutical Consulting
Aldar S. Bourinbaiar
MD, PhD · Co-Founder (1957–2024)
Founder of Immunitor; co-inventor of the V1/V5/V7 science and the Mongolia–Ukraine trial network.
Immunitor, USA
Who has examined our work
Independent investigators, on the record.
The most powerful answer to “too good to be true” is a stranger with credentials who looked at the science. Here is who studied the technology behind immugence — their institution, what they investigated, and exactly what they found. Every name links to the source.
Fully independentNo immugence / Immunitor author, no sponsorship
Independent trial sitesAcademic hospitals & cancer centers that ran the trials (our team as co-authors)
Dr. Galyna A. Kutsyna
Luhansk State Medical University · Ukraine
Dept. of Infectious Diseases
Co-led the Ukrainian clinical trials of oral immunotherapy in TB and TB/HIV co-infection.
Dr. Olga V. Arjanova & team
Lisichansk Regional TB Dispensary · Ukraine
Prihoda · Yurchenko · Sokolenko · Frolov
Ran adjunct-immunotherapy trials in re-treated, multidrug-resistant and HIV-coinfected TB.
Dr. Dmitry A. Butov
Kharkiv National Medical University · Ukraine
TB immunotherapy trialist
Led Phase IIb and Phase III trials of oral TB immunotherapy (V5 / Immunoxel).
Dr. Jigjidsuren Chinburen & team
National Cancer Center of Mongolia
Batchuluun · Munkhzaya · Purevsuren
Conducted the Phase II/III liver-cancer trials of hepcortespenlisimut-L (V5) in advanced HCC.
We label these honestly: the trial-site investigators led the studies at their own institutions, with our team as co-authors and sponsor; the fully-independent tier had no connection to us at all. Investigational research — not a treatment claim.
In the media
Reported by others — verify for yourself.
Independent press covering the founding team's work, 2011–2025. Each opens at its original source in a new tab. Distinct from the peer-reviewed evidence above.
immugence opens a new chapter for Thai medicine — the country's first DNA-based therapeutics forum
Hosted under ECG Immunitor, with global researchers (Jonathan Wong, Holland Cheng, Pisut Pongchaikul) and senior officials from Thailand's Ministry of Higher Education, Science, Research & Innovation, the Ministry of Public Health, and BIOTEC in attendance.
Read at THE STANDARD“It may sound futuristic — even too good to be true — but it rests on molecular biology and genetic data, backed by extensive research and rigorous testing at every step.”
— THE STANDARD, on the science behind immugence
More coverage of the founding lineage
Immunitor releases positive results of TB immunotherapy from its second clinical site
Read full articleKey Capital leads oral-pill vaccines race with Immunitor partnering and strong patenting
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines — 23 products
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines
Read full articleImmunitor releases positive Phase IIb TB immunotherapy results — second clinical site
Read full articleKey Capital licenses Immunitor oral-pill immunotherapeutic vaccines
Read full articleIndependent third-party coverage of the Immunitor lineage · each link opens at its original source.
Patient voices
Optional moduleHuman stories — not treatment claims.
These are personal, consented accounts from individuals who chose to take part in research. They describe people's experience, not medical results. They are not evidence of efficacy, not typical, and not a substitute for medical advice.
Before you watch
The stories behind this gate are individual experiences shared with consent. They are not medical claims, not typical results, and not a substitute for professional medical advice. immugence candidates are investigational and not registered medicines.
For the scientists & clinicians
Still not convinced?
Here is everything.
Everything above is the short version. If you want the full evidentiary record — every publication with its PMID, every patent, every designation, the preclinical datasets and the institutions that have backed this work — open the complete dossier.
Twenty-eight papers, by area — click any to verify at its source
Exact counts of the papers laid out on this page — 27 live PubMed links plus one open-access journal. The founding authors' full PubMed record exceeds 70; counting independent studies of the V-1 → V-7 products, 100+. These 28 are the ones we put in front of you to click.
33 papers individually linked below — every one resolves on PubMed, a DOI, or PMC · the founders' full author record runs to 100+ → live links at the end
V7 therapeutic TB vaccine — Phase III double-blind RCT
Hepcortespenlisimut-L in advanced HCC — Phase II
V5 adjunct immunotherapy in DS / relapsed / MDR-TB — Phase IIb
Hepcortespenlisimut-L for HCC — Phase III interim
Immunoxel honey lozenge adjunct in pulmonary TB — Phase III
V7 (M. vaccae, Longcom) oral pill in TB — Phase II RCT
V-1 Immunitor as a therapeutic modality for HIV — Phase II
HIV-antibody serodeconversion after V-1 Immunitor
Oral V-5 Immunitor in chronic hepatitis C — open-label
Adipose-derived oral preparation V-6 — safety & efficacy
Independent validation — peer-reviewed work with NO immugence / Immunitor author
The rest of the V-series record — every link resolves on PubMed, a DOI, or PMC. Don't take our word for it. The final group is the founding scientist's foundational antiviral research (pre-Immunitor, incl. two PNAS papers).
Read the complete corpus yourself — the founders' full author records, live on PubMed:
Patent portfolio — 6 flagship of 27+
Composition of matter, process, and methods of use. Vichai Jirathitikal, principal inventor.
Portfolio of 27+ incl. regional filings (EU/JP/CN/AU) and recent (2023+) Mg²⁺ antisense applications (ASFV, WSSV targets).
Government & preclinical datasets
Independent Thai government-laboratory results on the Mg²⁺ antisense platform.
Mg²⁺ antisense vs. African Swine Fever Virus
NSTDA / BIOTEC, WOAH-compliant qPCR + TCID50. ASFV genome reduced 17× (p=0.0009). PI: Dr. Teeradet Taweeratsilp.
BIOTEC P-2350898 · 2023Maxboost — shrimp immune priming
In vivo P. vannamei; phagocytosis +58% at day 14 (p<0.001). PI: Suparat Taengchaiyaphum.
NSTDA / BIOTEC · 2026Plant — cassava mosaic disease (CMD/SLCMV)
Field trials, Department of Agriculture + NSTDA + Mahidol.
DOA field programInstitutions that have backed this work
Independent validation a first-time team rarely assembles.
Bill & Melinda Gates Foundation
R&D support since the early 2000s; 3 joint grants via Grand Challenges Canada (HIV/AIDS + TB).
OTC:KCPC — Key Capital Corporation
Nov 2020 exclusive licensing of 23 oral products across the Americas, EU, AU/NZ — incl. 3 FDA-orphan candidates.
US Department of State
Science & Technology Entrepreneurship Program funded the founding team's work (science diplomacy).
US FDA — Office of Orphan Products Development
Designation #457714 granted (HCC, 2014); DRU-2019-7145 filed (TB, 2019).
Global network — 6 countries, 4 continents
Where the research, trials, IP and partnerships actually live.